{
  "docId": "019de516-a80e-7369-bef2-cb942c391804",
  "docSlug": "7dbeec795af717930d34b2c0014ea723",
  "documentTitle": "Oculis | Results Presentation Deck | 33 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 33,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "other",
  "function": "establish_context",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de516-a80e-7369-bef2-cb942c391804/10",
  "deckHref": "/decks/019de516-a80e-7369-bef2-cb942c391804",
  "deckJsonHref": "/decks/019de516-a80e-7369-bef2-cb942c391804.json",
  "deckAnchorHref": "/decks/019de516-a80e-7369-bef2-cb942c391804#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.34,
        "w": 0.65,
        "x": 0.17,
        "y": 0.51
      },
      "kind": "diagram",
      "text": "N = 241\nEnd of treatment\n2 Weeks\nOCS-01 1x/day (QD)\nVehicle 1x/day (QD)\nOff Treatment\n10 Weeks\nSafety assessments and Endothelial Cell Density\nSafety assessments and endothelial cell density\nScreening and Baseline evaluations (prior to surgery)\nSurgery day and Randomization 1:1\nDrug administration started on Day 1 after cataract surgery",
      "attrs": {},
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b59a463d-c479-471d-bc42-012656a26a73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.36,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "list",
      "text": "Key Inclusion Criteria\nAge ≥18 years\nPlanned unilateral cataract extraction using phacoemulsification and PCIOL implantation\nACC score ≥ 2 at Visit 2 (Day 1, 18-30 hours post-uncomplicated surgery)\nPin-hole VA > 20 letters (20/400) in study eye and > 35 letters (20/200) in fellow eye using ETDRS at Visit 1",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fbf601c6-8454-4cbe-9820-4100f8c23557",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.43,
        "x": 0.41,
        "y": 0.25
      },
      "kind": "list",
      "text": "Endpoints\nHierarchical Primary Efficacy Measures:\n1. Absence of anterior chamber cells (i.e. score of 'o') at Visit 6 (Day 15)\n2. Absence of pain (i.e. score of 'o') at Visit 4 (Day 4)\nSafety Measures: IOP, Endothelial Cell Density and AEs",
      "attrs": {},
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6290fe6b-76c5-4375-88ea-0c1a9441ca43",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.026,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "A multi-center, randomized, double-masked, vehicle-controlled, phase 3 trial of OCS-01 (OPTIREACH®-dexamethasone 15 mg/mL ophthalmic formulation)",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df629ba2-98d0-4cac-a9fc-596432056258",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.94,
        "x": 0.026,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "ACC: anterior chamber cells; AE:adverse event; ETDRS: Early Treatment Diabetic Retinopathy Study; IOP: intraocular pressure; PCIOL: posterior chamber intraocular lense; QD: once daily; VA: visual acuity.\nData, analysis, and conclusions are preliminary, and subject to change as full analysis is ongoing.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f359911-2856-42d1-bd7b-85fc22b729fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.82,
        "x": 0.026,
        "y": 0.037
      },
      "kind": "title",
      "text": "OPTIMIZE Trial Evaluated OCS-01 for Treatment of Inflammation and Pain Following Cataract Surgery",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3cf23752-26fc-4946-9bd0-f060500fbe86",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 7,
      "beatId": "bf8d92bd-d10c-44d0-8929-d028af75265a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document further agitates the problem by presenting detailed clinical data on the OPTIMIZE trial and current treatment limitations (slides 7-10).",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    },
    {
      "to": 24,
      "from": 8,
      "beatId": "7992b42b-1916-498c-b92e-c9642604a8e5",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents OCS-01 as a solution, highlighting its efficacy, safety, and potential value to stakeholders (slides 8-24).",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5d7f0e87-f17e-4730-84ac-15c62ad2ef1a",
      "evidence": "The document implies the cost of inaction by highlighting the limitations of current treatments and the potential benefits of OCS-01.",
      "position": 0,
      "objective": "What are the consequences of not addressing post-ocular surgery inflammation and pain effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 24,
      "from": 8,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "8c374baa-88d9-4915-a041-aab0dfbd527a",
      "evidence": "The document presents OCS-01 as a solution that addresses the needs of patients and healthcare providers.",
      "position": 1,
      "objective": "How can OCS-01 address the needs of patients and healthcare providers in ocular surgery?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}